Sunnyside Raises $11.5M Series A to Expand Its Wellness Platform

The company will invest in enhancing the product experience for its app, which helps members strive for balanced alcohol use.

Written by Ashley Bowden
Published on Nov. 15, 2023
Sunnyside Raises $11.5M Series A to Expand Its Wellness Platform
Nick Allen, CEO and co-founder of Sunnyside, poses for a photo.
Nick Allen, CEO and co-founder of Sunnyside. | Photo: Sunnyside / Built In

Aiming to revamp the alcohol health space, Sunnyside offers an app and program to help its members incorporate mindful drinking habits into their lives. The company raised $11.5 million in a Series A capital round. Spearheaded by Motley Fool Ventures, the money will go toward enhancing Sunnyside’s product experience and furthering its mission.

Sunnyside’s goal is for the proactive management of alcohol consumption to become as common and socially accepted as managing diet, exercise and mindfulness. Rather than emphasizing complete sobriety, the company’s alternative approach to alcohol health focuses on moderation and balance without adding pressure to quit drinking entirely. Sunnyside’s platform was previously featured in Built In’s Future 5, a series highlighting unique local startups.

“By shifting the conversation from the language of addiction and recovery to one of managing alcohol as a proactive investment in our wellbeing, we can help millions of people make a profound positive impact on their lives,” Nick Allen, CEO and co-founder of Sunnyside, said in a statement. “Seeing that the Sunnyside approach is already working for tens of thousands of members is what motivates our work each and every day.”

Sunnyside’s new capital will help it work toward pioneering mindful drinking as the next popular wellness category. The fresh funding will help Sunnyside fuel product enhancements that will expand the social connections among its member community. It also plans to introduce Sunny, an AI-powered coach for mindful drinking. 

Hiring Now
Benchling
Cloud • Healthtech • Software • Biotech